The modified vaccination technique designed to prevent and cure acute and chronic disorders.

In spite of enormous efforts there have been no solutions to date for preventing/terminating certain acute and chronic disorders of humans by vaccination or drugs. Yet it is well understood that if the target antigen (ag) could be presented appropriately to the cells of the immune system then solutions could be found. Recently, the Barabas research group has introduced and described the third vaccination method - called modified vaccination technique (MVT) - which has the ability to provide a corrective immune response in experimental animals with an autoimmune kidney disease.

Suppression of tumor growth by a heterologous antibody directed against multiple myeloma dominant CD38 antigen in SCID mice injected with multiple myeloma cells.

Employing passive immunization - using a heterologous anti-CD38 IgG antibody containing serum - in SCID mice injected subcutaneously with human multiple myeloma cells, we have shown that treatments with the antiserum - especially in the presence of complement - significantly decreased cancer growth. However, administered antibody and complement was not sufficient in amount to prevent cancer cell multiplication and cancer growth expansion to a satisfactory degree. Larger volumes of the same components more than likely would have further reduced cancer growth and prolonged the life of mice.

Elevated antibody response by antigen presentation in immune complexes.

Background: Active immunization techniques against exogenous source antigens (ags - such as bacteria, virus) proved to be successful in preventing many acute infectious diseases from occurring in a susceptible population. However, an active immunization technique that could be employed both prophylactically and therapeutically has so far not been described. We have developed a new vaccination technique that employs specific immune complex (IC) containing components which is able to redirect immune-response outcomes in both preventative and curative regimens in an experimental autoimmune kidney disease.